Jefferies initiates Sabesp stock with buy on efficiency potential

Jefferies initiated coverage of Sabesp (SBS) at Buy with a US$36.6 / BRL190 price target and projects the regulatory asset base to rise 70% by 2029; the stock trades at 1x EV/RAB and ~6.1x EV/EBITDA (2027) while P/E is 12.44 and EV/EBITDA 9.0. Sabesp reported Q4 2025 EPS of $0.5115, beating the $0.4617 consensus by ~10.8%, while revenue missed slightly at $1.08B vs $1.10B expected. Shares have rallied 17.9% YTD and 67% over the past year; Jefferies cites scope to improve operational efficiency and expand water/sewage coverage under supportive regulation. No M&A or analyst upgrades/downgrades were reported.

Analysis

Sabesp sits on a mechanically attractive cash-flow story: growth in regulated asset base converts into predictable tariff-recovery cashflows provided regulators allow full cost pass-through and WACC stability. The market discount appears driven less by fundamentals than by execution and political tail risk — lawmakers can compress returns via tariff lags or retroactive adjustments, turning a multi-year earnings glidepath into a volatile wait.

Second-order beneficiaries include local engineering and treatment-equipment vendors who will see multi-year backlog visibility as coverage expands; conversely, municipal budgets and politically exposed counterparties become de facto credit knobs that can transmit sovereign or fiscal stress into the utility’s allowed returns. FX is a non-trivial transmission mechanism for US-listed holders: capex funded in BRL but reported in USD creates a two-way sensitivity where BRL moves amplify USD returns.

The practical arb is therefore between contractual/regulatory certainty and EM policy risk. Near-term catalysts that re-rate the name are regulatory decisions confirming tariff formulas, announced capex schedules with financing that preserves credit metrics, or visible progress on coverage metrics that materially derisk execution. The main reversal scenarios are tariff freezes, an adverse court/regulatory precedent, or a BRL crash that forces emergency political action — any of which could compress valuations quickly.

Key Decisions for Investors

• Long SBS (ADR) — 12–36 month horizon. Size as a 1–2% NAV starter. Hedge ~50% currency exposure via short BRL forwards or buy USD/BRL calls to isolate regulatory/outcome risk. Risk/reward: asymmetric — if regulatory outcomes follow the stated capex plan the stock should re-rate toward EM peer multiples; if tariffs are frozen, expect a meaningful drawdown, so maintain tight stop-loss or hedge.
• Pair trade: Long SBS / Short XLU (or a basket of developed-market regulated utilities) — 12–24 months. This isolates EM regulatory upside vs developed-market multiple compression. Use equal notional exposure and rebalance quarterly; target 2:1 upside/downside when tariff approvals materialize vs adverse outcomes.
• Options entry (if liquid): Buy 18–30 month OTM calls on SBS (or buy-call LEAP) while selling near-term puts to fund premium, with max allocation 0.5–1% NAV. This captures the regulatory/capex de-risking path with defined downside (put assignment) and high convexity to a positive regulatory ruling. Close or roll if a tariff decision is delayed beyond announced timelines.
• Event trigger plan: If a regulatory ruling or tariff approval is delayed and SBS falls >10% intraday, add incrementally to long position and widen FX hedge; conversely, if a government signal indicates tariff freezes, cut exposure to under 0.5% NAV and switch to short-dated put protection. Time the build to 6–18 month regulatory calendar windows.